However, there are plenty of allergen-free options currently on the market that do meet these requirements
Some patients notice appetite changes within the first few weeks, but meaningful weight loss usually develops over months
Stated differently, FM loss occurred at a rate 2-3x higher than FFM loss
The treatment paradigm mirrors how we approach other chronic conditions: you take the medication as long as you need it, potentially for life
We need to treat it like one, just like we treat hypertension or high cholesterol. Two GLP-1 agonists and one dual GIP/GLP-1 agonist are currently FDA-approved to treat obesity
Additionally, GLP-1 receptor agonists may directly reduce gallbladder emptying and motility, potentially contributing to bile stasis and gallstone formation independently of weight loss effects